FDA Approves Glumetza
FDA Approves Glumetza for Type 2 Diabetes
Glumetza is a once-daily, extended-release formulation of metformin hydrochloride which may offer potential advantages such as less frequent dosing and fewer side effects. Glumetza is indicated for the treatment of Type 2 diabetes.Posted: June 2005
Related articles
- Depomed Receives FDA Approval for 1000 mg Strength Tablets of Glumetza - January 2, 2008
- Depomed, Biovail Update Status of Glumetza NDA - April 13, 2005
- Biovail, Depomed Receive Approvable Letter from FDA for Extended-Release Glumetza for Type II Diabetes - March 1, 2005
- Biovail, Depomed Announce Glumetza NDA Accepted by FDA - June 24, 2004
- Biovail and Depomed Submit NDA for Glumetza; Submission Includes 500mg and 1000mg dosages; Biovail/Depomed Expand Royalty Agreement to Include 1000mg dose - April 28, 2004
Glumetza (metformin extended release) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
